INOVIO Secures Orphan Drug Designation For INO-3107 From European Commission For Treatment Of Recurrent Respiratory Papillomatosis
Portfolio Pulse from Benzinga Newsdesk
INOVIO has secured Orphan Drug Designation for INO-3107 from the European Commission for the treatment of Recurrent Respiratory Papillomatosis.
May 23, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INOVIO's INO-3107 receives Orphan Drug Designation from the European Commission, potentially boosting the company's stock.
The Orphan Drug Designation for INO-3107 by the European Commission is a positive development for INOVIO. This designation can provide regulatory and financial incentives for the company, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100